VIR
Vir Biotechnology, Inc. NASDAQ Listed Oct 11, 2019$9.27
Mkt Cap $1.5B
52w Low $4.16
68.2% of range
52w High $11.66
50d MA $9.65
200d MA $6.84
P/E (TTM)
-3.2x
EV/EBITDA
-1.8x
P/B
1.8x
Debt/Equity
0.2x
ROE
-55.0%
P/FCF
-2.1x
RSI (14)
—
ATR (14)
—
Beta
1.66
50d MA
$9.65
200d MA
$6.84
Avg Volume
3.5M
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
499 Illinois Street · San Francisco, CA 94158 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.01 | -0.85 | -8400.0% | 10.29 | -4.2% | -9.9% | — | — | — | — | — |
| Feb 23, 2026 | AMC | -0.42 | -0.31 | +26.2% | 7.43 | +32.4% | +27.7% | +34.6% | +25.4% | +22.3% | +25.7% | — |
| Nov 5, 2025 | AMC | -0.70 | -1.17 | -67.1% | 5.40 | -5.0% | -5.2% | -5.0% | -0.6% | +5.7% | +5.7% | — |
| Aug 6, 2025 | AMC | -0.72 | -0.80 | -11.1% | 5.08 | -5.1% | -14.4% | -15.4% | -15.7% | -14.2% | -10.0% | — |
| May 7, 2025 | AMC | -0.83 | -0.88 | -6.0% | 5.61 | -3.2% | -3.6% | -9.3% | -5.5% | -16.2% | -19.8% | — |
| Feb 26, 2025 | AMC | -0.85 | -0.76 | +10.6% | 9.20 | +3.8% | -11.8% | -8.8% | -13.9% | -10.9% | -10.7% | — |
| Oct 31, 2024 | AMC | -0.96 | -1.56 | -62.5% | 7.49 | -4.7% | +23.6% | +25.1% | +28.7% | +35.8% | +30.4% | — |
| Aug 1, 2024 | AMC | -0.93 | -1.02 | -9.7% | 9.73 | -3.6% | -5.3% | -11.1% | -11.6% | -14.6% | -11.4% | — |
| May 2, 2024 | AMC | -0.99 | -0.48 | +51.5% | 9.18 | +10.3% | +13.2% | +11.3% | +8.2% | +3.9% | +4.1% | — |
| Feb 22, 2024 | AMC | -1.14 | -0.86 | +24.6% | 10.30 | +1.9% | +11.9% | +15.5% | +11.0% | +12.6% | +9.1% | — |
| Nov 2, 2023 | AMC | -1.21 | -1.22 | -0.8% | 8.19 | +1.7% | +7.0% | +5.4% | +3.1% | +4.9% | -0.6% | — |
| Aug 3, 2023 | AMC | -1.21 | -1.45 | -19.8% | 13.97 | -0.4% | -2.5% | -7.2% | -4.3% | -3.4% | -4.2% | — |
| May 4, 2023 | AMC | -0.81 | -1.06 | -30.9% | 25.50 | -3.4% | -3.9% | -5.3% | -4.9% | -4.2% | -4.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.91 | $9.20 | +3.3% | +7.3% | +2.1% | +7.2% | +10.0% | +10.9% |
| Feb 25 | Barclays | Maintains | Overweight → Overweight | — | $9.49 | $9.82 | +3.5% | +5.4% | -1.8% | -4.2% | -1.6% | -6.1% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $7.43 | $9.84 | +32.4% | +27.7% | +34.6% | +25.4% | +22.3% | +25.7% |
| Feb 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.43 | $9.84 | +32.4% | +27.7% | +34.6% | +25.4% | +22.3% | +25.7% |
| Feb 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $7.43 | $9.84 | +32.4% | +27.7% | +34.6% | +25.4% | +22.3% | +25.7% |
| Feb 9 | Needham | Maintains | Buy → Buy | — | $7.19 | $7.19 | +0.0% | +1.3% | +4.5% | +3.2% | +7.2% | +3.9% |
| Dec 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.98 | $5.94 | -0.7% | -2.3% | +0.8% | -0.7% | -3.2% | -0.3% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.00 | $5.02 | +0.4% | -4.2% | -2.8% | -4.0% | +3.6% | +3.6% |
| Aug 27 | BofA Securities | Upgrade | Neutral → Buy | — | $4.44 | $4.98 | +12.2% | +17.8% | +13.5% | +11.3% | +12.6% | +24.1% |
| May 22 | Needham | Maintains | Buy → Buy | — | $4.51 | $4.45 | -1.3% | +2.2% | -0.2% | +3.3% | +5.5% | +15.1% |
| May 12 | Needham | Maintains | Buy → Buy | — | $5.09 | $5.17 | +1.6% | +4.1% | -7.7% | -11.6% | -10.6% | -9.6% |
| Apr 17 | Goldman Sachs | Maintains | Buy → Buy | — | $5.44 | $5.40 | -0.7% | +1.1% | +3.1% | +6.6% | +9.7% | +15.6% |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | $8.11 | $8.10 | -0.1% | +3.5% | -2.3% | +1.1% | +1.4% | -0.5% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.11 | $8.10 | -0.1% | +3.5% | -2.3% | +1.1% | +1.4% | -0.5% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $9.20 | $9.55 | +3.8% | -11.8% | -8.8% | -13.9% | -10.9% | -10.7% |
| Jan 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.31 | $10.31 | +0.0% | +0.9% | -3.2% | -5.9% | -2.5% | -0.8% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $12.10 | $11.94 | -1.3% | -13.1% | -15.5% | -13.2% | -16.9% | -16.4% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.48 | $12.69 | +1.7% | -3.0% | -15.7% | -18.0% | -15.9% | -19.5% |
| Jan 9 | JP Morgan | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Jan 9 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | — | — | — | — | — | — | — | — |
| Nov 20 | Needham | Maintains | Buy → Buy | — | $6.93 | $6.86 | -1.0% | -2.7% | +0.3% | +2.7% | +7.4% | +10.0% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.93 | $6.86 | -1.0% | -2.7% | +0.3% | +2.7% | +7.4% | +10.0% |
| Nov 4 | Barclays | Maintains | Overweight → Overweight | — | $9.26 | $9.26 | +0.0% | +1.2% | +4.1% | +9.8% | +5.5% | +3.7% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.26 | $9.26 | +0.0% | +1.2% | +4.1% | +9.8% | +5.5% | +3.7% |
| Nov 1 | Needham | Maintains | Buy → Buy | — | $7.49 | $7.14 | -4.7% | +23.6% | +25.1% | +28.7% | +35.8% | +30.4% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.77 | $8.83 | +0.7% | +0.5% | -1.1% | -5.1% | +0.0% | -1.7% |
| Aug 2 | Barclays | Maintains | Overweight → Overweight | — | $9.73 | $9.38 | -3.6% | -5.3% | -11.1% | -11.6% | -14.6% | -11.4% |
| Jun 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.66 | $12.89 | +1.8% | -5.4% | -11.3% | -11.5% | -16.0% | -17.2% |
| Jun 5 | Needham | Maintains | Buy → Buy | — | $10.58 | $12.18 | +15.1% | +19.7% | +13.2% | +6.1% | +6.0% | +0.5% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.58 | $12.18 | +15.1% | +19.7% | +13.2% | +6.1% | +6.0% | +0.5% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.65 | $10.75 | +0.9% | -0.9% | +0.8% | -5.2% | -2.4% | -3.6% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.22 | $10.34 | +1.2% | -2.8% | -6.7% | -6.5% | -7.6% | -4.4% |
| May 3 | JP Morgan | Maintains | Neutral → Neutral | — | $9.18 | $10.13 | +10.3% | +13.2% | +11.3% | +8.2% | +3.9% | +4.1% |
| May 3 | Needham | Maintains | Buy → Buy | — | $9.18 | $10.13 | +10.3% | +13.2% | +11.3% | +8.2% | +3.9% | +4.1% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.52 | $10.47 | -0.5% | +2.3% | +1.5% | -4.9% | -3.3% | -4.1% |
| Feb 23 | JP Morgan | Maintains | Neutral → Neutral | — | $10.30 | $10.50 | +1.9% | +11.9% | +15.5% | +11.0% | +12.6% | +9.1% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.85 | $9.10 | +2.8% | +10.6% | +16.5% | +15.8% | +15.6% | +14.2% |
| Jan 29 | JP Morgan | Downgrade | Overweight → Neutral | — | $9.55 | $8.94 | -6.4% | -0.3% | -1.6% | -1.6% | -4.5% | -9.2% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.60 | $9.77 | +1.8% | +3.9% | +0.3% | +1.0% | -0.5% | -0.8% |
| Nov 3 | Needham | Maintains | Buy → Buy | — | $8.19 | $8.33 | +1.7% | +7.0% | +5.4% | +3.1% | +4.9% | -0.6% |
| Sep 8 | BofA Securities | Downgrade | Buy → Neutral | — | $11.56 | $11.14 | -3.6% | -4.8% | -7.2% | -9.3% | -13.5% | -13.1% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.62 | $13.50 | -0.9% | -4.8% | -1.8% | -0.9% | -1.8% | -1.8% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $13.97 | $13.92 | -0.4% | -2.5% | -7.2% | -4.3% | -3.4% | -4.2% |
| Jul 21 | Goldman Sachs | Maintains | Buy → Buy | — | $12.70 | $12.98 | +2.2% | +13.0% | +10.5% | +10.2% | +10.6% | +8.3% |
| Jul 21 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.70 | $12.98 | +2.2% | +13.0% | +10.5% | +10.2% | +10.6% | +8.3% |
| Jul 21 | Barclays | Maintains | Overweight → Overweight | — | $12.70 | $12.98 | +2.2% | +13.0% | +10.5% | +10.2% | +10.6% | +8.3% |
| Jul 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.05 | $13.70 | -40.6% | -44.9% | -37.7% | -39.1% | -39.3% | -39.0% |
| Jul 20 | Needham | Maintains | Buy → Buy | — | $23.05 | $13.70 | -40.6% | -44.9% | -37.7% | -39.1% | -39.3% | -39.0% |
| May 5 | Needham | Maintains | Buy → Buy | — | $25.50 | $24.64 | -3.4% | -3.9% | -5.3% | -4.9% | -4.2% | -4.9% |
| Apr 19 | Needham | Maintains | Buy → Buy | — | $25.00 | $24.93 | -0.3% | +0.4% | -1.0% | +3.9% | +1.6% | -0.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | SATO VICKI LDir | — | Sell | 22,000 | $10.05 | $221K | 1,078,391 | -1.67% | — |
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary contains only technical XBRL metadata without substantive business information about Vir Biotechnology's financial results, transactions, or strategic developments.
Apr 10
8-K
Vir Biotechnology, Inc. -- 8-K Filing
I cannot provide a meaningful investor summary from this filing, as the document contains only technical SEC metadata and structural references without disclosing substantive business developments, financial results, or corporate actions affecting Vir Biotechnology.
Mar 4
8-K
Vir Biotechnology, Inc. -- 8-K Filing
Vir Biotechnology filed an 8-K disclosure confirming its status as an emerging growth company under SEC regulations, which may affect its reporting obligations and compliance requirements.
Mar 2
8-K
Vir Biotechnology, Inc. -- 8-K Filing
Vir Biotechnology established standard underwriting protections through representations, warranties, and indemnification provisions in a securities offering agreement with underwriters.
Feb 26
8-K · 8.01
!! High
Vir Biotechnology, Inc. -- 8-K 8.01: Material Event / Announcement
Vir Biotechnology will present updated Phase 1 data for cancer candidate VIR-5500 at an upcoming oncology conference, potentially influencing investor sentiment on the drug's development progress.
Feb 23
8-K · 7.01
! Medium
Zura Bio Limited Class A -- 8-K 7.01: Regulation FD Disclosure
Zura Bio disclosed material information via press release on February 23, 2026, subject to Regulation FD requirements without admitting materiality determinations for investor consideration.
Feb 23
Data updated apr 27, 2026 7:44am
· Source: massive.com